Differences in the rate of nicotine metabolism among smokers with and without HIV.

Abstract

OBJECTIVE\nHIV-infected smokers lose more life years to tobacco use than to HIV infection. The nicotine metabolite ratio (NMR), a biomarker of CYP2A6, represents individual variation in the rate at which nicotine is metabolized and is associated with response to smoking cessation treatments. We evaluated whether HIV-infected smokers metabolize nicotine faster than HIV-uninfected smokers, which may contribute to the disproportionate smoking burden and may have important treatment implications.\n\n\nDESIGN\nWe analysed baseline data from two clinical trials (NCT01710137; NCT01314001) to compare the NMR in HIV-infected smokers (N\u200a=\u200a131) to HIV-uninfected smokers (N\u200a=\u200a199).\n\n\nMETHODS\nPropensity scores were used to match the groups 2\u200a:\u200a1 on characteristics that influence NMR: sex, race, BMI and smoking rate. Nicotine metabolites were assessed via liquid chromatography-tandem mass spectrometry methods and the ratio of 3-hydroxycotinine:cotinine was used to compute the NMR.\n\n\nRESULTS\nHIV-infected smokers had significantly higher NMR (mean\u200a=\u200a0.47, SEM\u200a=\u200a0.02) and were more likely to be in the highest NMR quartile compared with HIV-uninfected smokers (mean\u200a=\u200a0.34, SEM\u200a=\u200a0.02; Ps\u200a<\u200a0.001).\n\n\nCONCLUSION\nThe higher NMR observed among HIV-infected smokers may partially explain higher smoking rates and lower response to transdermal nicotine therapy. Understanding the mechanisms by which HIV and/or ART contribute to faster nicotine metabolism may guide the use of the NMR to personalize tobacco cessation strategies in this underserved population.